These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3150903)

  • 1. Clinical significance of lymphokine-activated killer activity in childhood acute lymphoblastic leukemia.
    Kato M
    Acta Paediatr Jpn; 1987 Apr; 29(2):206-13. PubMed ID: 3150903
    [No Abstract]   [Full Text] [Related]  

  • 2. A recycling defect as a characteristic of natural killer cells in childhood acute lymphoblastic leukemia.
    Yabuhara A; Kawai H
    Pediatr Res; 1990 Dec; 28(6):572-8. PubMed ID: 2284152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation.
    Foa R; Guarini A; Gillio Tos A; Cardona S; Fierro MT; Meloni G; Tosti S; Mandelli F; Gavosto F
    Cancer Res; 1991 Feb; 51(3):964-8. PubMed ID: 1988139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased natural killer cell activity and numbers of Leu-7 and Leu-11b (CD 16)-positive cells in bone marrow of children in remission from acute lymphoblastic leukaemia.
    Sørskaar D; Førre O; Lie SO
    Scand J Immunol; 1989 Jan; 29(1):65-72. PubMed ID: 2466327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Dysfunction After Completion of Childhood Leukemia Therapy.
    Perkins JL; Harris A; Pozos TC
    J Pediatr Hematol Oncol; 2017 Jan; 39(1):1-5. PubMed ID: 27820131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Natural killer activity--an index of the efficacy of the treatment of patients with acute leukemia].
    Gashchuk AP; Evtukh VP; Kindzel'skiĭ AL
    Lik Sprava; 1994; (5-6):79-81. PubMed ID: 7831919
    [No Abstract]   [Full Text] [Related]  

  • 7. Interleukin 2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia--a phase I study.
    Weisdorf DJ; Anderson PM; Blazar BR; Uckun FM; Kersey JH; Ramsay NK
    Transplantation; 1993 Jan; 55(1):61-6. PubMed ID: 8420066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro enhancement of natural killer cell activity against herpesvirus-infected targets in patients with acute lymphocytic leukemia.
    McKolanis JR; Ragab AH; Schmid DS
    Arch Virol; 1991; 117(1-2):17-28. PubMed ID: 1848749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of adult acute lymphoblastic leukemia blasts to lysis by lymphokine-activated killer cells.
    Archimbaud E; Thomas X; Campos L; Magaud JP; Fiere D; Doré JF
    Leukemia; 1991 Nov; 5(11):967-71. PubMed ID: 1961038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-2 before and/or after autologous bone marrow transplantation for pediatric acute leukemia patients.
    Messina C; Zambello R; Rossetti F; Gazzola MV; Varotto S; Destro R; Basso G; Semenzato G; Zanesco L
    Bone Marrow Transplant; 1996 May; 17(5):729-35. PubMed ID: 8733689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased cytotoxic potential of fresh and recombinant interleukin 2-cultured large granular lymphocytes in childhood acute lymphoblastic leukemia.
    Yamada S; Miyagawa Y; Komiyama A
    Leuk Res; 1991; 15(5):367-72. PubMed ID: 2046388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute lymphoblastic leukemia of NK-cell lineage: responses to IL-2.
    Pirruccello SJ; Bicak MS; Gordon BG; Gajl-Peczalska K; Gnarra DJ; Coccia PF
    Leuk Res; 1989; 13(9):735-43. PubMed ID: 2796381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant interleukin-2 activates peripheral blood lymphocytes from children with acute leukemia to kill autologous leukemic cells.
    Findley HW; Abdel Mageed A; Nasr SA; Ragab AH
    Cancer; 1988 Nov; 62(9):1928-31. PubMed ID: 3262410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: experience of the BFM study 86.
    Ludwig WD; Harbott J; Bartram CR; Komischke B; Sperling C; Teichmann JV; Seibt-Jung H; Notter M; Odenwald E; Nehmer A
    Recent Results Cancer Res; 1993; 131():269-82. PubMed ID: 8210646
    [No Abstract]   [Full Text] [Related]  

  • 15. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
    Scheid C; Pettengell R; Ghielmini M; Radford JA; Morgenstern GR; Stern PL; Crowther D
    Bone Marrow Transplant; 1995 Jun; 15(6):901-6. PubMed ID: 7581089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced versus intensive chemotherapy for childhood acute lymphoblastic leukemia: impact on lymphocyte compartment composition.
    van Tilburg CM; van der Velden VH; Sanders EA; Wolfs TF; Gaiser JF; de Haas V; Pieters R; Bloem AC; Bierings MB
    Leuk Res; 2011 Apr; 35(4):484-91. PubMed ID: 21051085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-2 induction of lymphokine-activated killer activity in the peripheral blood of an acute lymphoblastic leukaemia patient--case study.
    Dickinson AM; Lennard AL; Cartner R; Proctor SJ
    Leukemia; 1992 Sep; 6(9):957-60. PubMed ID: 1518307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Studies on the mechanism of liver injury by lymphokine-activated killer cell].
    Mizoguchi Y; Kondo Y; Kodama C; Sakagami Y; Seki S; Kobayashi K; Yamamoto S; Morisawa S
    Nihon Shokakibyo Gakkai Zasshi; 1988 Jul; 85(7):1390-7. PubMed ID: 3263521
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of ultraviolet B irradiation on human natural killer cell and lymphokine activated killer cell activity: therapeutic potential in bone marrow transplantation and tumor immunotherapy.
    Yaron I; Zakheim AR; Oluwole SF; Hardy MA
    Transplant Proc; 1995 Feb; 27(1):1379. PubMed ID: 7878918
    [No Abstract]   [Full Text] [Related]  

  • 20. [Augmentation of lymphokine-activated killer (LAK) cell activity by combination of low dose interleukin 2 and several kinds of biological response modifiers (BRMs)].
    Ohnishi H; Okuno K; Nakamura T; Nakamura Y; Yasutomi M
    Nihon Gan Chiryo Gakkai Shi; 1988 Oct; 23(10):2539-45. PubMed ID: 3264846
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.